We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
Pact Coffee is an online seller of roasted coffee beans. All of Pact Coffee's beans are shipped within 7 days of roasting as this is when they taste the best. With the money invested, Pact look to develop new products and expand into 2 new european countries.      
days to go: Expired investment: £195,400
Love Cocoa are a British Chocolate company founded by James Cadbury, descendant of John Cadbury, founder or the Cadbury confectionery company. The organic chocolate bars are handmade in the UK using the finest ingredients and sourced from independent British producers such as Maldon Sea Salt.
days to go: Expired investment: £198,410
Vita Mojo is an award winning food technology company, providing affordable meals tailored specifically to the customer. The food is personal and transparent as to what goes into each dish and how it was prepared. All ingredients are picked to suit your own tastes and needs, and can be personalised to increase your protein or decrease your calories as required. 
days to go: Expired investment: £3,200,080
A 100% natural, healthy and nutritious snack company created for children. Chewymoon's snack boxes contain 1 of 5 a day foods and are less than 100 kcal. The boxes also comes with collectible stickers and cards for children to enjoy. Chewymoon has sold over 220,000 snacks directly from its website and is planning to expand into retail stores. Orders have increased by more than 400% from 6,135 orders in Dec 17 to 31,245 in Jun 18.
days to go: Expired investment: £369,860
Yumbles is a leading UK online marketplace for artisan food. It currently connects over 600 independent food makers directly with consumers. The company is targeting the UK’s estimated £10bn+ UK Speciality Food & Drink market, having seen £1m+ sales in the last 12 months resulting in £400k+ revenue.
days to go: Expired investment: £262,080
Rabble is a gamified and licensed fitness program that transforms exercise into fun, team-based games. It was first formed by a former international athlete and then financed by investors from the LA Fitness & Liverpool football club. Rabble has quickly risen to 100 authorized sites strengthening many healthy communities over the UK. It is a differentiated concept which is named as Global Fitness Trend (WGSN). It has a proven and scalable model where the market leaders earn revenue of more than $100m. Further, it has developed 100+ instructors across the UK in less than one year. Rabble aims at helping and changing more lives with the finance that it raises. It is planning to grow to more than 300 Rabble sites in the coming year.
days to go: Expired investment: £274,530
MysteryVibe creates doctor-recommended sexual health devices. The company combines research and engineering by onboarding leading doctors to design devices that address major sexual health issues such as erectile dysfunction, dryness and pain during intercourse. MysteryVibe has changed over 50,000 lives in 65 countries, witnessed $1 million worth of direct sales in 2020, and became the first sexual health startup to be featured on a BBC documentary. The company has received 20+ international awards including, the coveted Design Week Awards where its product, 'Crescendo', beat the Apple Watch. MysteryVibe has featured in media entities like Men's Health, Women's Health, The Daily Dot, and Forbes, to name a few. The company will use 25% of the investment to expand and scale its digital marketing campaign, 25% to launch two new products, 25% to expand its team, and 25% on building its inventory.

Pitch Rated

82%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £498,020
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph